NLRP3 and Parkinson disease: Given the role of HDAC6 specific inhibitors in inflammatory conditions (de Zoeten et al., 2011; Di Liddo et al., 2016; Chang et al., 2018; Karki et al., 2019; Ran and Zhou, 2019), we examined whether NLRP3 is a potential molecular target of HDAC6 for the regulation of cellular events in PD.